Abstract
Oncogenic fusions are major drivers in leukemogenesis and may serve as potent targets for treatment. DUX4/IGHs have been shown to trigger the abnormal expression of ERG alt through binding to DUX4-Responsive-Element (DRE), which leads to B-cell differentiation arrest and a full-fledged B-ALL. Here, we determined the crystal structures of Apo- and DNA DRE -bound DUX4 HD2 and revealed a clamp-liketransactivation mechanism via the double homeobox domain. Biophysical characterization showed that mutations in the interacting interfaces significantly impaired the DNA binding affinity of DUX4 homeobox. These mutations, when introduced into DUX4/IGH, abrogated its transactivation activity in Reh cells. More importantly, the structure-based mutants significantly impaired the inhibitory effects of DUX4/IGH upon B-cell differentiation in mouse progenitor cells. All these results help to define a key DUX4/IGH-DRE recognition/step in B-ALL.
Cite
CITATION STYLE
Dong, X., Zhang, W., Wu, H., Huang, J., Zhang, M., Wang, P., … Meng, G. (2018). Structural basis of DUX4/IGH-driven transactivation. Leukemia, 32(6), 1466–1476. https://doi.org/10.1038/s41375-018-0093-1
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.